Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.

You may also be interested in...



PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

Growth of post-market surveillance system also may require more resources.

Pradaxa Bleeding Events Prompt FDA To Revise Generic Bioequivalence Criteria

Revamped ANDA instructions – among new and revised draft guidance for 58 products announced by FDA – 'account for the fact that dabigatran exhibits large within-subject variability with respect to blood levels.'

Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement

Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel